Brief: Sprint Bioscience Q4 Operating Loss SEK 14.7 Million
Feb 15 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q4 OPERATING LOSS SEK 14.7 MILLION VERSUS LOSS SEK 15.1
MILLION
YEAR AGO
* Q4 NET SALES SEK 0 VERSUS SEK 0.7 MILLION YEAR AGO
* PROPOSES NO DIVIDEND FOR 2022
Source text for Eikon: ID:nMFN4Plj2Z
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln